LeadBio Completes Nearly RMB 100 Million Series A Financing Led by Panlin Capital

VCBeat exclusively learned that recently, a research and development platform for regenerative repair materials and artificial organs regenerationLEADBIO (hereinafter referred to as "LEADBIO")Completed nearly 100 million yuan in Series A financing. This round of financing was led byPanlin CapitalLead Investment,TAILONG VC, Huada Win Win (Shenzhen) Equity Investment Fund Management Co., Ltd.Follow-up investment, and existing shareholdersTigerYeah Capital, Beijing Qiwo Boxing Management Consulting Co., Ltd.Continued to increase investment in this round.

Under the capital winter, as a new generation innovative medical device enterprise, LEADBIO's successful completion of a large-scale financing fully demonstrates the capital market's high recognition and optimism towards its team and the niche track it is in.

The funds from this Series A round will mainly be used for the registrational clinical trials of the company’s biological artificial blood vessels, while continuously advancing the research and development of other pipelines and further improving the construction of the company’s technology achievement transformation platform.

LEADBIO is committed to becoming a globally leading platform enterprise in the research, development, and manufacturing of tissue regeneration, repair, and regenerative artificial organs.

According to reports, LEADBIO was co-founded by a seasoned team in the medical industry and Professor Kong Deling, the current director of the State Key Laboratory of Drug Chemistry and Biology at Nankai University. The company aims to become a world-class regenerative medicine product company and a cutting-edge technology commercialization platform for medical devices.

LEADBIOBiological Artificial Blood VesselBased on the innovative technology and preparation process fully independently developed by Professor Kong Deling's team, the combination of polymer materials and bioactive decellularized matrix has been successfully achieved. This technical approach not only provides excellent mechanical properties for artificial blood vessels but also enhances their biocompatibility and long-term patency. After the implantation of this artificial blood vessel in patients, the meticulously designed scaffold structure and extracellular matrix layer will promote the adhesion, proliferation, and migration of endothelial cells, ultimately enabling the rapid endothelialization of the artificial blood vessel. This significantly reduces the incidence of vascular stenosis and blockage.

Currently, in the completed controlled formal animal trials, LEADBIO's artificial blood vessels have demonstrated significantly superior performance compared to artificial blood vessels made of polymer materials; in the completed scientific clinical trial for arteriovenous fistula involving 20 patients, LEADBIO’s biological artificial blood vessels also showed excellent clinical outcomes. According to information disclosed by LEADBIO, the product is about to enter the pivotal clinical trial stage.

In addition, the results of preliminary studies indicate that LEADBIO's bio-artificial blood vessel has significant application potential in coronary artery bypass grafting indications. Currently, LEADBIO is collaborating with top cardiac surgery teams in China to conduct preclinical research in this direction.

As a platform enterprise positioned in the transformation of cutting-edge scientific and technological achievements, LEADBIO adheres to the principles of "technology platform sharing" and "product complementarity," and has currently establishedThree Major Technical Platforms: Decellularized Matrix, 3D Printing, and Hydrogel, multiple products incubated under this platform will also enter the registration clinical trial stage in the near future.

Among them,LEADBIO's Radiation Therapy Isolation Protection Hydrogel Product, which was co-developed with the Institute of Biomedical Engineering, Chinese Academy of Medical Sciences. This is another heavyweight medical device product from LEADBIO that has been successfully transformed through collaboration with domestic research institutions, following the bio-type artificial blood vessel.

Chairman of LEADBIO, Professor Kong DelingStated: "First of all, we would like to express our heartfelt gratitude to Panlin Capital, the leading investor of this round of Series A financing, for their strong support for the company. Like many innovative companies, LEADBIO takes original technological innovation as the core driving force for enterprise development. On the other hand, it also incorporates more communication on clinical market demands and the R&D capabilities and cutting-edge achievements of various scientific research institutes." LEADBIO's "small-caliber biological artificial blood vessels’It is the first technology transfer product under this development strategy. The project has not only demonstrated excellent preliminary clinical research results but also participated in a major research and development plan by the Ministry of Science and Technology. In the future, through the fundamental research base of 'LEADBIO-Nankai University Joint Laboratory,' the company will strive to bring more revolutionary products to patients. At the same time, with our management and technology transfer experience in cutting-edge biotechnology, we hope to assist more scientists in achieving the industrialization of scientific and technological achievements, and more efficiently convert research outcomes into innovative medical device products that meet clinical needs.”

As the lead investor in LEADBIO's Series A financing,Li Yuhui, Founding Managing Partner of Panlin CapitalComment: "LEADBIO is a successful case of scientific and technological achievement transformation in China's regenerative medicine tissue engineering field, and also a typical 'source innovation' enterprise in the eyes of Panlin Capital. Its product technology platform is based on nearly 20 years of scientific research exploration by Professor Kong Deling. By combining the globally pioneering 3D scaffold printing with subcutaneous implantation in animals, it has solved the technical difficulties of small-caliber blood vessels and ensured the continuous expansion of the product pipeline. Particularly commendable is that the company’s progress in the development of regenerative blood vessels for coronary artery bypass surgery is internationally leading, and if successful, will have epoch-making significance. We look forward to the company, under the leadership of Chairman Professor Kong Deling and CEO Xu Pengyun—a management team highly complementary in technology and business—smoothly advancing the clinical pipelines for arteriovenous fistula and coronary artery bypass, and further evolving into a globally leading R&D enterprise for small-caliber regenerative blood vessels."

Founder and General Manager of TigerYeah Capital, Dr. Jirong Ji"It has been verified in clinical trials that LEADBIO's biological artificial blood vessel has good surgical operation characteristics and a high long-term patency rate, meeting the clinical needs of dialysis patients. We hope it can be launched as soon as possible to provide a new high-quality option for dialysis patients in China."

Sun Jun, Executive Director of TAILONG VC"It shows that: 'The artificial blood vessel products have a huge import substitution market. Existing research data indicates that LEADBIO's biological artificial blood vessels demonstrate significant clinical advantages compared to imported polymer material blood vessel products. They belong to the next generation of products in the artificial blood vessel field and are expected to reshape the competitive landscape of this field.'"。”

Huada Win Win (Shenzhen) Equity Investment Fund Management Co., Ltd. Partner Ji Changtao"Regenerative medicine is a field we have been paying close attention to. The industrialization prospects of artificial blood vessels are enormous, and different technical routes such as polymer materials, ECM, and stem cells can all be realized. LEADBIO’s technology is mature, and its products have entered a milestone stage. The team demonstrates balanced capabilities in science, technology, and business. We look forward to the successful commercialization of the company's products, which will benefit the people."。”

Boxing Capital Cong BoStated: "LEADBIO's biotechnology has global leadership and is one of the few companies in China that fully relies on self-developed products to solve clinical problems. The company's biological artificial blood vessels have been validated for product efficacy and safety in dialysis fistula, and the product layout has been completed in areas such as coronary artery bypass and peripheral bypass. Boxing Capital continued its investment in this round, fully trusting the company’s team capabilities and firmly optimistic about the future development opportunities of the products."。”

Panlin Capital was founded in 2010, adhering to the investment theme of "Technology creates the future, innovation leads upgrading," and is committed to "discovering entrepreneurs among scientists and nurturing innovators among entrepreneurs." It is a venture capital institution in China that possesses both professionalism and influence in the two major fields of healthcare, To B, and technology.

In the medical field, Panlin Capital focuses on the prevention, diagnosis, and treatment of major diseases, investing in new drug development companies and high-end medical device import substitution enterprises, as well as derivative opportunities arising during industry development. It has successively invested in companies such as CanSino Biologics (300601), Apollomics (APLM), Hybribio (300639), RiboBio, Shengnovo, Virogin, Affinity, ZhiXinHaoZheng, and Goldschmeding Bio in their early stages.

Panlin Capital is also a growth-stage investment institution for A-share listed companies such as TanLabs (300005), Golder Environmental (603588), Oriental Fashion (603377), Junmeng Games (acquired and merged by Fuchun Co., Ltd. 300299), and Sunstory (acquired and merged by Royal Group 002329).

TigerYeah Capital was established in 2014 as an independent venture capital institution under Tigermed. TigerYeah Capital focuses on equity investments in early and growth-stage healthcare sectors. The management team has a deep industry background, extensive industry resources, and rich investment experience. To date, it has completed investments totaling 20 billion yuan across more than a hundred projects. Its investment portfolio covers medical devices, biopharmaceuticals, CRO, and health foods. By empowering its invested companies, TigerYeah Capital creates value for the development of the healthcare industry in China and globally, contributing to public health.

TAILONG VC was established in 2021 as a professional equity investment management institution focusing on the biopharmaceuticals, medical devices, and healthcare sectors, with a fund management scale of 20 billion RMB. TAILONG VC has a professional and experienced investment team, prioritizing investments in biopharmaceuticals, innovative medical devices, core CXO services and innovation fields, and outstanding biopharmaceutical industry funds. It is committed to building a value investment platform for the biopharmaceutical industry that stays true to science and spans economic cycles.

Huada Win Win (Shenzhen) Equity Investment Fund Management Co., Ltd., as a venture capital investment institution with an industrial background in BGI, combines the dual advantages of CVC and VC institutions in terms of industrial resources and flexible decision-making mechanisms. It advocates the investment philosophy of "R&D-driven investment," focusing on full-stage investment coverage of high-quality projects within the bioeconomy sector, including gene technology, cutting-edge biopharmaceuticals, innovative medical devices, food nutrition, and biomaterials. The firm is committed to becoming a top-tier innovative investment management institution in the bioeconomy field, achieving shared resources and win-win development among industrial resources, fund investors, and investment projects.

Boxin Capital is an early-stage medical investment venture capital firm founded by partners with extensive experience in the healthcare industry. It currently manages funds with a total scale of nearly 2 billion RMB, focusing on more than 40 innovative medical device and healthcare service companies with significant market potential. Many of these companies have grown into leaders in their respective niche markets, and Boxin Capital has successfully completed profitable exits for several projects. The investors behind Boxin Capital include top-tier domestic fund-of-funds, healthcare industry entrepreneurs, and seasoned investors. With in-depth industry research, clear investment logic, and comprehensive post-investment management capabilities, Boxin Capital has gained continuous support from its investors, earned long-term respect from entrepreneurs, and firmly established itself as a long-term partner for top-tier investors and entrepreneurs in China.